IMC Immuron

Immuron Presentation Australian Biologics Festival 2024

Immuron Presentation Australian Biologics Festival 2024

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia.

A copy of the presentation slide deck is available on the Company’s website.

Authorised for release by the Board of Immuron Limited.



COMPANY CONTACT:

Steven Lydeamore

Chief Executive Officer

Ph: +61 (0)3 9824 5254

        		  



About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit:



EN
21/02/2024

Underlying

IMCImmuron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immuron

 PRESS RELEASE
Free
IMC IMMURON

Immuron to host Live Virtual Event

Immuron to host Live Virtual Event MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday, April 29 at 8pm EDT. TRAVELAN® BOUND FOR PHASE 3 CLINICAL TRIALSExploring Immuron’s Positive Phase 2 Travelan® Results and Upc...

April 15, 2024 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Travelan® sales continued strong growth

Immuron Travelan® sales continued strong growth Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter   Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcpMar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter   USA FYTD Mar 2024 AUD$0.8 million up 35% on pcpMar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarterSales commenced on Walmart.com MELBOURNE, Australia, Apr...

April 10, 2024 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Announces Positive Results Support Travelan® progress to Phase...

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group compared to the placebo group (primary endpoint)66.7% protective efficacy against ETEC induced severe diarrhea was observed in the Travelan® group compared to the placebo group (se...

March 7, 2024 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Presentation Australian Biologics Festival 2024

Immuron Presentation Australian Biologics Festival 2024 MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia. A copy of the presentation slide deck is available on the Company’s website. Authorised for release by the Board of Immuron Limited. COMPANY CONTACT:Steven LydeamoreCh...

February 21, 2024 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron achieves record Travelan® sales

Immuron achieves record Travelan® sales Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan® YTD Jan 2024 sales $2.1 millionUSA Travelan® YTD Jan 2024 sales $0.6 millionCanadian sales recommenced through McKesson MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacte...

February 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch